Sanger Heart & Vascular Institute Symposium 2015 · Sanger Heart & Vascular Institute Symposium...
Transcript of Sanger Heart & Vascular Institute Symposium 2015 · Sanger Heart & Vascular Institute Symposium...
S a n g e r H e a r t & Va s c u l a r I n s t i t u t e S y m p o s i u m 2 0 1 5
Cardiovascular Update For Primary Care Physicians
Glen A Fandetti, MD, FACC, FSCAICardiovascular Medicine and Interventional Cardiology
Sanger Heart and Vascular Institute
Evaluation and Management of Acute Pulmonary Embolism
1/26/2015 2
Sanger Heart & Vascular Institute Symposium 2015
Disclosures
I have nothing to disclose
1/26/2015 3
Sanger Heart & Vascular Institute Symposium 2015
Why is a Cardiologist speaking about Pulmonary Embolism (PE)?
• These patients often present with:– Chest Pain– Arrhythmias– Leg Pain and Edema– Hemodynamic Instability: Hypotension, Cardiac Arrest– Abnormal Cardiac Imaging Studies & Biomarkers
• VTE shared risk factors with many cardiac disease states:-Advanced age, Smoking, CHF, Diabetes, HTN, Sedentary lifestyle
1/26/2015 4
Sanger Heart & Vascular Institute Symposium 2015
Burden of VTE (Venous Thromboembolism): Acute PE & DVT
VTE kills more people each year than breast cancer, HIV, and traffic accidents…combined1,2
– Estimates of >200,000 deaths each year in US attributable to DVT/PE1,3,4
– Affects 1/1000 people annually – ~600,000 hospitalizations annually in
the United States for DVT and/or PE5
– Healthcare costs associated with DVT/PE in 2011 are estimated to be up to $10 billion1
4
CDC Reported Causes of Annual Deaths in the United States
41,078
9406
36,216
100,000
0
20,000
40,000
60,000
80,000
100,000
120,000
BreastCancer
HIV TrafficAccidents
VTE2
*
2
2 1
CDC = Centers for Disease Control and Prevention.*An estimated 100,000 deaths each year are attributable to DVT/PE.1. Centers for Disease Control and Prevention. http://www.cdc.gov/NCBDDD/AboutUs/documents/NCBDDD_StrategicPlan_2‐10‐11.pdf. Accessed September 11, 2012. 2. Centers for Disease Control and Prevention. http://www.cdc.gov/nchs/data/nvsr/nvsr60/nvsr60_60_03.pdf. Accessed October 3, 2012. 3. Heit JA. Arterioscler Thromb Vasc Biol. 2008;28:370‐372. 4. Heit J et al. Blood. 2005;106:267A. 5. Centers for Disease Control and Prevention. MMWR. 2012;61(22):401‐404.
1/26/2015 5
Sanger Heart & Vascular Institute Symposium 2015
There is Renewed Interest in Venous Thromboembolism (VTE) Management?
• Novel oral anticoagulants with FDA approved VTE indication• More Data from Large Scale Thrombolysis Trials
– PEITHO (NEJM 2014) • Increased Role For Cardiovascular Expertise:
– Echo imaging for Acute RV strain diagnosis– Analysis of cardiac biomarkers– Education: Pulmonary HTN and Venous disease– Evolving Endovascular Therapies for VTE
• Support for System Wide Best Practice Algorithms for Acute PE Care: CODE PE
1/26/2015 6
Cardiovascular Update For Primary Care Physicians 2015
1/26/2015 7
Sanger Heart & Vascular Institute Symposium 2015
Case36 year old female on OCP for uterine fibroids w recurrent bleeding is 1 week s/p recent severe L ankle sprain.-Urgent care prescribed partial weight bearing . -She chose bedrest & develops L calf pain which progresses proximally-Office with PCP:
-Now describes R lower rib cage pain (thought secondary to her crutch)-Exam: Mild Respiratory distress, L leg/thigh swelling, RR-20O2sat 90% on RA, BP 108/80
……Next steps?
1/26/2015 8
Sanger Heart & Vascular Institute Symposium 2015
Venous Thromboembolism (VTE)Diagnostic Testing Pathways
• Testing for DVT and PE involves 3 components:– Clinical risk assessment (probability)– Blood Tests (D-Dimer)– Vascular Imaging
1/26/2015 9
Sanger Heart & Vascular Institute Symposium 2015
Case: ECG
ST‐ HR ~110
PE Evaluation and Diagnosis: Modified Wells
• Pretest probability:– Low (<2 points)– Intermediate (2-
6 points)– High (>6 points)
VARIABLE POINTS
S/S of DVT 3.0
HR >100 1.5
Immobilization (bed rest >/= 3d) OR surgery within 4 weeks
1.5
Prior DVT or PE 1.5
Hemoptysis 1.0
Malignancy (treated within the past 6 months or palliative
1.0
Other diagnoses less likely than PE 3.0
Evaluation and imaging is dependent upon estimated pretest probability (Modified Wells Criteria)
1/26/2015 11
Sanger Heart & Vascular Institute Symposium 2015
Venous Thromboembolism (VTE)Clinical Risk Assessment
Patients with High or Intermediate risk can be treated while waiting for results of further diagnostic tests
-Patients with Low risk may not need imaging tests
DVT and PE are both VTE, but they are NOT the same• They have different clinical implications and one can be
present without the other• BUT…..
The Acute Treatment for both is essentially the same
1/26/2015 12
Cardiovascular Update For Primary Care Physicians 2015
1/26/2015 13
Cardiovascular Update For Primary Care Physicians 2015
1/26/2015 14
Sanger Heart & Vascular Institute Symposium 2015
D-Dimer Testing• Elevated in plasma in the presence of acute
thrombolysis – Due to simultaneous activation of coagulation and fibrinolysis
• HIGH NEGATIVE PREDICTIVE VALUE– Normal D-Dimer renders acute VTE unlikely
• LOW POSITIVE PREDICTIVE VALUE– Fibrin split products are very common in a variety of conditions:
• Cancer• Inflammation• Bleeding • Trauma Positive D-Dimer unhelpful in this case
• Surgery• Necrosis
1/26/2015 15
Sanger Heart & Vascular Institute Symposium 2015
Testing for DVTLower Extremity Duplex U/S
• First line• High sensitivity/specificity for
DVT– Whole leg >> Proximal veins only
• Can miss proximal (iliac) DVT– CTV if pretest probability high
• Widely available• Cost Effective
1/26/2015 16
Cardiovascular Update For Primary Care Physicians 2015
Death
V T E R i s k F a c t o r s
Small DVT
Big DVT
PE
~10%
~50%
<5%
1/26/2015 17
Cardiovascular Update For Primary Care Physicians 2015
resolve
30-50%
<5%
post-thrombotic syndrome
Death
V T E R i s k F a c t o r s
Small DVT
Big DVT
PE
~10%
~50%
<5%
thromboembolicpulmonary
hypertension
90%
1/26/2015 18
Sanger Heart & Vascular Institute Symposium 2015
Venous Thromboembolism (VTE)• Vascular Imaging for PE
• Multi-Detector CT (MDCT)– Has replaced V/Q scanning for diagnosis of PE– High radiation dose is problematic – Iodinating contrast can be nephrotoxic
• Ventilation/perfusion (V/Q) lung scanning– Consider in:
• Pregnancy (perfusion only)• Severe CKD• Contrast Allergy
• Pulmonary Angiogram– For patients undergoing heart cath once ACS is ruled out– For planned endovascular intervention
1/26/2015 19
Cardiovascular Update For Primary Care Physicians 2015
Testing for PEMDCT: Multi‐Detector CTA Gold Standard
Rapid, Sensitivity/Specificity>90%; assesses RV strain, PE burden; R/o tamponade & aortic dissection
PE
RV/LV Ratio
1/26/2015 20
Sanger Heart & Vascular Institute Symposium 2015
CaseLabs: -Chem7-wnl, Hgb ~10.2-trop < .04-cBNP 30-D- Dimer >150
MDCT:R Lower Lobe segment PEPartially obstructedRV/LV <.8
1/26/2015 21
Sanger Heart & Vascular Institute Symposium 2015
Acute PE – Risk Stratification• Not based solely on
radiologic findings• The presence of “lots” of
VTE isn’t enough to call it “massive”
• Need to determine clinical picture– Co-morbidities– Risk of hemodynamic
collapse• Syncope,shock arrest
– Cardiac arrest– Syncope
Risk Stratifying Acute PE
Cardiac Biomarkers
Trop I>.14 ng/mlcBNP >90 pg/ml
Clinical DataPESI Index
AgeRisk Factors
Vitals
RV StrainOn MDCT or Echo
RV/LV >.9&
Clot Burden and Location
Acute PERisk
1/26/2015 23
Cardiovascular Update For Primary Care Physicians 2015
Mortality:
70-95% 20-50% 5-10% < 3%
Cardiac arrest
Clinical High Risk PE
(Massive)
Intermediate Risk PE
(Submassive)
Low-Risk PE(Nonmassive)
extensive PE hypotension overt RHF
extensive PE no hypotension
sPESI>1 RVD on echo Tp, BNP
~5% ~5% ~30% ~60%
Acute PE
BNP = brain natruiretic peptide; RHF = right heart failure; RVD = right ventricular dysfunction; Tp = troponin
sPESI=0 no RV strain nl Tp, BNPSubsegmental clot
1/26/2015 24
Cardiovascular Update For Primary Care Physicians 2015
1/26/2015 25
Cardiovascular Update For Primary Care Physicians 2015
Cardiospecific Biomarkers• Troponin ‐ released from right ventricle Injury
• Cardiac BNP ‐ released from cardiac myocytesin response to elevated pressures
• A normal troponin and BNP can safely exclude high risk patients with a negative predictive value of 97‐100%
(Kucher et al; Circulation 2003;108:2191-4)
Trop I > .14 ng/ml
> 90 pg/ml
1/26/2015 26
Sanger Heart & Vascular Institute Symposium 2015
RV Strain• An RV/LV ration of >.9 was shown to be and
independent predictive factor for HOSPITAL MORTALITY
• RV hypokinesis on baseline echo following PE with a ~40% higher mortality rate
1/26/2015 27
Sanger Heart & Vascular Institute Symposium 2015
Echocardiogram: RV Strain
1/26/2015 28
Cardiovascular Update For Primary Care Physicians 2015
Low Risk PE definition
• Patients with the lowest short‐term mortality in acute PE are those who are:– normotensive with normal biomarker levels
– no RV dysfunction on imaging– sPESI =0
She is not Low Risk because of sPESI >1
1/26/2015 29
Cardiovascular Update For Primary Care Physicians 2015
1/26/2015 30
Cardiovascular Update For Primary Care Physicians 2015
Intermediate Risk (Submassive) PE definition
• Acute PE without systemic hypotension (systolic blood pressure 90 mm Hg) but with either:– RV dysfunction
• Hypokinesis• Dilitation: RV/LV diameter >.9 on MDCT or Echo• BNP >90 pg/ml • Appropriate ECG Changes (RBBB, etc.)
– Myocardial necrosis • Troponin I >.14ng/ml
1/26/2015 31
Sanger Heart & Vascular Institute Symposium 2015
Intermediate Risk PE therapy• ANTICOAGULATION (AC)- HEPARIN
– AC therapy prevents further clot growth– Consider Single Drug NOAC’s for stable patients
• Oxygen supplementation• Telemetry monitoring
1/26/2015 32
Cardiovascular Update For Primary Care Physicians 2015
1/26/2015 33
Sanger Heart & Vascular Institute Symposium 2015
Thrombolysis in Acute PE
• ‘The decision to administer a fibrinolytic agent in addition to heparin anticoagulation requires individualized assessment of the benefits vs risks’
• Potential Benefits:– Rapid resolution of symptoms (SOB, CP, distress)– Stabilization of CV/respiratory status w/out ventilator or pressor
support– Reduce RV damage and decrease pulm HTN– Harms: Major & Minor Bleeding
1/26/2015 34
Cardiovascular Update For Primary Care Physicians 2015
Lysis and Intracranial hemorrhage:Efficacy at the cost of safety
Study Intracranial Hemorrhage (Fibrinolysis
Group)ICOPER(Goldhaber SZ, et al. 1999)
9/304 (3%)
PEITHO (Meyer G, et al. 2014)
10/506 (2%)
1/26/2015 35
Sanger Heart & Vascular Institute Symposium 2015
The Larger the Dose, the greater the Risk!!!
1/26/2015 36
Sanger Heart & Vascular Institute Symposium 2015
EKOS: Low Dose Ultrasound Facilitated Localized Thrombolysis.
Concept: Ultrasound causes reversible disaggregation and separation of un-cross-linked fibrin fibers, increasingthrombus penetration of thrombolyticdrugs.
ULTIMA Trial. Kucher N, et al. Circulation 2014;129:479-486.
1/26/2015 37
Sanger Heart & Vascular Institute Symposium 2015
Endovascular Therapy for Acute PE
1/26/2015 38
Cardiovascular Update For Primary Care Physicians 2015
Thrombolysis in Acute PE (PEITHO)
SubmassivePE* R
Standard therapy: IV heparin > 48 h LMWH overlapping with warfarin
Standard therapy + IV bolus tenecteplase
Follow-up
x 1 mo.N~1,000
2007-2010G. Meyer
Primary outcome: composite of all-cause mortality + hemodynamic collapse (CPR, sBP <90 >15 min) within 7 daysSecondary outcomes: death, hemodynamic collapse, recurrent symptomatic PE, stroke, major bleeding within 7days; death <30 days
*RV dysfunction on echo or CTPA + elev troponin but normal BP
1/26/2015 39
Sanger Heart & Vascular Institute Symposium 2015
Case
• 18 hours after initiating LMWH, ptdeveloped excessive menstrual bleeding, diaphoresis
• Hgb Dropped to < 8• Otherwise, patient remained stable on tele
with improvement in her O2 Saturation • Anticoagulation d/c following
recommendation of OB/Gyn consult • Next step?
1/26/2015 40
Sanger Heart & Vascular Institute Symposium 2015
Case: Retrievable Filter Placed
• Big Concern:• Up to 80% are NOT removed!
1/26/2015 41
Cardiovascular Update For Primary Care Physicians 2015
Accepted Indication for an IVC Filter
Uncertain (controversial) indications: • Big DVT + poor cardiopul. reserve• “Recurrent” VTE/failure of Rx• Primary prophylaxis
Recent PROXIMAL DVT or PEPLUS an absolute contra-indication to full
anticoagulation
1/26/2015 42
Sanger Heart & Vascular Institute Symposium 2015
Case: VideoFilter Retrieval
1/26/2015 43
Cardiovascular Update For Primary Care Physicians 2015
1/26/2015 44
Cardiovascular Update For Primary Care Physicians 2015
High-Risk (Massive) PE definition
• Acute PE with: – Cardiac arrest / hemodynamic instability– sustained hypotension
• systolic blood pressure 90 mm Hg for at least 15 minutes OR requiring inotropic support not due to a secondary cause (arrhythmia, sepsis)
• Remember: The presence of “lots” of PE isn’t enough to call it “massive”
1/26/2015 45
Sanger Heart & Vascular Institute Symposium 2015
Suspected High-Risk PE• Initial care should consist of:
– Systemic Anticoagulation ASAP– Supplemental oxygen for O2 sat <90%– Admit to the intensive care unit:
• Significant hypoxemia • Hemodynamic compromise
– Mechanical ventilation for respiratory failure– For Hypotension:
• IVF• Vasopressor Support
0%
10%
20%
30%
40%
50%
60%
70%
RVPO(Echo)
Hypotension Shock CPR
In‐Hospital M
ortality
Mortality Spectrum in PE
W Kasper. J Am Coll Cardiol 1997;30:1165‐1171/ Konstantinides
1/26/2015 47
Cardiovascular Update For Primary Care Physicians 2015
1/26/2015 48
Cardiovascular Update For Primary Care Physicians 2015
Surgical Embolectomy• PE with shock without time for or
contraindication to systemic thrombolytic therapy (Grade 2C).
• RA clot/paradoxical (PFO) associated with VTE
• High mortality/morbidity but can be life saving
1/26/2015 49
Sanger Heart & Vascular Institute Symposium 2015
Intraoperative Photo
R
L
1/26/2015 50
Cardiovascular Update For Primary Care Physicians 2015
Who can help me with this
Acute PE?
ED Cards Pulm Hospitalis
t
Yawn…the trop & BNP seem too low to be serious.
Show me the data for
Rx of Submassive
PE.
Cards read the Echo, so….
Pre CODE PE
1/26/2015 51
Sanger Heart & Vascular Institute Symposium 2015
Code PE Program:The Vision
– Increase Acute VTE Public Awareness– Seek multidisciplinary clinical input
• By phone (or bedside if emergent)– Identify clinical experts
• Multi-Specialty• Pharmacy• PCP/Outpatient Anticoagulation Clinics
– Utilize Best Practice Treatment Algorithms– Standardize Order Sets & CANOPY Notes– Create CHS Acute PE Registry– Track our Outcomes as New Treatment Strategies are
Implemented“A great way of improving relationships/collaboration among multiple specialties”
1/26/2015 52
Cardiovascular Update For Primary Care Physicians 2015
1/26/2015 53
Sanger Heart & Vascular Institute Symposium 2015
Duration of Anticoagulation
1/26/2015 54
Sanger Heart & Vascular Institute Symposium 2015
44%↓
JUPITER: Rosuvastatin Prevents VTE• VTE pre-specified secondary endpoint of
JUPITER– Symptomatic PE– Symptomatic DVT
• Rosuvastatin decreased occurrence of VTE
– 43% reduction VTE (p=0.007)– Significant reductions in both
provoked and unprovoked events– Driven by reduction in symptomatic
DVT• Postulated mechanisms
– Beneficial downstream effects of statins on the coagulation profile via effects on signaling proteins
– ↓ tissue factor, Factor II expression– ↓ Factors V, VII activation– ↑ protein C activity
N Engl J Med 2009; 360:1851.
LDL cholesterol < 130 mg/dL and hs‐CRP > 2 mg/L
1/26/2015 55
Sanger Heart & Vascular Institute Symposium 2015
VTE & CODE PE Management 2015
• Know who is at risk for VTE• Make the correct Diagnosis• Rapid LMWH or UFH• Risk Stratify your PE patients using the proper tools• Treat the Subtype of PE appropriately….CODE PE• Attempt to define the duration of anticoagulation post PE
Statin• Ensure proper clinical follow-up
Thank you!
[email protected](m) 704‐975‐3199